Protocol 652-2-202: A Phase 2b Randomized, Double-Blind, Double-Dummy Trial of 100 or 200 mg Once-Daily Doses of Cenicriviroc (CVC, TBR-652) or Once-Daily EFV, Each With Open- Label FTC/TDF, in HIV-1-Infected, Antiretroviral Treatment-Naive, Adult Patient